Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.
The Brighton, England-based clinical-stage biotechnology company, focused on the development of novel medicines that can prevent life-threatening infections said the completion of a partnering agreement for its NTCD-M3 phase 3 drug is expected for early 2023.
The company said it had entered exclusive negotiations with a US pharmaceutical company to secure a commercialisation partner for NTCD-M3 - its lead asset for the prevention of clostridioides difficile infection recurrence.
Destiny Pharma also said a US and EU phase 3 development place had been defined for its XF-73 nasal gel for the prevention of post-surgical infections. The company said its target is to secure a commercialisation partner for the drug in 2023, with some early discussions already underway.
Chief Executive Officer Neil Clark said: ‘Our aim is to end 2023 having secured partners for both of our lead assets to complete their final Phase 3 clinical studies, registration and approval in key markets - especially the United States.’
The company said good progress had also been made on its earlier pre-clinical pipeline programmes and has ended 2022 with two active dermal infection projects running in the US and China, and with the completion of the SporCov Covid-19 grant-funded collaboration, with further updates expected in the first half of 2023.
Destiny Pharma shares were up 12% trading at 37.65 pence per share on Thursday morning in London.
By Harvey Dorset, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2022 Alliance News Ltd. All Rights Reserved.